Julie A. Stone - Concepedia

Author

Julie A. Stone

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

J A Stone, J Stone, J. A. Stone, J. Stone, J.A. Stone, Julie A Stone, Julie A. Stone, Julie Stone, Julie A. Stone

134

Publications

5.2K

Citations

H-Index

123

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy Covance (United States)Vanderbilt University

About

Julie A. Stone is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	34	2.6K
2	Public Health	4	4	242
3	Health Sciences	2	2	73
4	Engineering	1	1	27
5	Natural Sciences	1	1	161

Julie A. Stone

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients Matthew Kennedy, Andrew W. Stamford, Xia Chen, Science Translational Medicine Glucose HomeostasisBace1 Inhibitor VerubecestatEnzyme 1Social SciencesNeuroinflammation	2016	407
Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men Julie A. Stone, Sherry D. Holland, Peter Wickersham, Antimicrobial Agents and Chemotherapy	2002	246
Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents Thomas J. Walsh, Peter C. Adamson, Nita L. Seibel, Antimicrobial Agents and Chemotherapy	2005	238
Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance David C. Turner, Anna Kondic, Keaven M. Anderson, Clinical Cancer Research	2018	205
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill, Journal of Medicinal Chemistry Neurochemical BiomarkersPeptide ScienceEnzyme 1Chemical BiologyAlzheimer ’	2016	161
Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir Larissa Wenning, William D. Hanley, Diana M. Brainard, Antimicrobial Agents and Chemotherapy ImmunologyPharmacotherapyAntimicrobial ChemotherapyAntiviral DrugDrug Resistance	2009	160
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer Manash Chatterjee, David C. Turner, Enriqueta Felip, Annals of Oncology MedicinePembrolizumab DosingImmune Checkpoint InhibitorPharmacotherapySystematic Evaluation	2016	158
Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies S. Aubrey Stoch, Stefan Zajic, Julie A. Stone, Clinical Pharmacology & Therapeutics	2009	156
Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age Xavier Sáez‐Llorens, M. Macías, P. P. Maiya, Antimicrobial Agents and Chemotherapy NeonatologyCandida InfectionsInfant NutritionPharmacologyPediatrics	2008	138
Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma Julie A. Stone, Xin Xu, Gregory A. Winchell, Antimicrobial Agents and Chemotherapy Physiologically-based Pharmacokinetic ModelingMedicineParenteral Antifungal DrugRadioactivity ExcretionPathology	2004	137

Page 1